Status:

UNKNOWN

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Lead Sponsor:

Chiasma, Inc.

Conditions:

Acromegaly

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of...

Detailed Description

This is a double blind, randomized study that assesses the efficacy and safety of octreotide capsules vs. placebo. Eligible acromegaly patients, treated with injectable somatostatin analogs, who are b...

Eligibility Criteria

Inclusion

  • Documented evidence of active acromegaly
  • Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least 6 months with a stable dose for at least the last three months of therapy
  • Biochemically controlled

Exclusion

  • Patients taking injections of long-acting Somatostatin Receptor Ligands (SRLs) not as indicated in the label
  • Pituitary surgery within six months
  • Conventional or stereotactic pituitary radiotherapy any time in the past
  • Patients who previously participated in CH-ACM-01 or OOC-ACM-302
  • Any clinically significant uncontrolled concomitant disease
  • Symptomatic cholelithiasis
  • Pegvisomant, within 24 weeks
  • Dopamine agonists, within 12 weeks
  • Pasireotide, within 24 weeks

Key Trial Info

Start Date :

September 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2022

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT03252353

Start Date

September 1 2017

End Date

May 1 2022

Last Update

November 23 2020

Active Locations (60)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (60 locations)

1

Keck Medical Center of University of Southern California

Los Angeles, California, United States, 90033

2

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

3

UCLA Medical Center

Los Angeles, California, United States, 90095

4

Stanford University School of Medicine

Palo Alto, California, United States, 94304

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly | DecenTrialz